Mirogabalin

Mirogabalin (brand name Tarlige; developmental code name DS-5565) is a gabapentinoid medication developed by Daiichi Sankyo. Gabapentin and pregabalin are also members of this class. As a gabapentinoid, mirogabalin binds to the α₂δ subunit of voltage-gated calcium channel (1 and 2), but with significantly higher potency than pregabalin. It has shown promising results in Phase II clinical trials for the treatment of diabetic peripheral neuropathic pain.^[1][2]

Mirogabalin

Clinical data
Trade names	Tarlige
Other names	DS-5565
Routes of administration	By mouth
ATC code	N02BF03 (WHO)
Identifiers
IUPAC name (1R,5S,6S)-6-(aminomethyl)-3-ethyl-bicyclo(3.2.0)hept-3-ene-6-acetic acid
CAS Number	1138245-13-2 Y
PubChem CID	49802951
ChemSpider	32701007
UNII	S7LK2KDM5U
KEGG	D11203
CompTox Dashboard (EPA)	DTXSID001032301
Chemical and physical data
Formula	C12H19NO2
Molar mass	209.289 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCC1=CC2C(C1)C[C@@]2(CN)CC(=O)O
InChI InChI=1S/C12H19NO2/c1-2-8-3-9-5-12(7-13,6-11(14)15)10(9)4-8/h4,9-10H,2-3,5-7,13H2,1H3,(H,14,15)/t9-,10-,12-/m1/s1 Key:FTBQORVNHOIASH-CKYFFXLPSA-N

Phase III trial results:

• Effective: for post-herpetic neuralgia (trial: NEUCOURSE)
• Ineffective: for fibromyalgia (trial: ALDAY)^[3]
• Effective: for diabetic peripheral neuropathic pain (trial: REDUCER)^[4]

In Japan, the company submitted a marketing application for treatment of peripheral neuropathic pain.^[5] The medication was approved for neuropathic pain and postherpetic neuralgia in Japan in January 2019.^[6]